CT Air-trapping for the Early Identification of Benralizumab Responders Among Eosinophilic Asthma Patients
Status:
Recruiting
Trial end date:
2022-06-20
Target enrollment:
Participant gender:
Summary
BenraliScan aims to obtain thoracic computed tomography imaging data to predict the future
level of patient response to a monoclonal antibody. Because the clinical responses under
study can take many months to manifest, early identification of patients most-likely to
benefit from treatment and treatment rule-out for others will save considerable time for
everybody involved.
The primary objective of BenraliScan is to determine the prognostic value (sensitivity,
specificity, positive predictive value, negative predictive value) of air-trapping measures
(Expiratory/Inspiratory ratios for Mean Lung Density (MLDe/i)) detected via quantitative
thoracic computed tomography at baseline for improvement in exacerbation rate (the presence
of a ≥50% reduction in baseline exacerbation rate versus the absence of a ≥50% reduction in
baseline exacerbation rate) at 52 weeks among eosinophilic asthma patients treated with
Benralizumab.